Thangavadivel, Shanmugapriya <br/><br/>
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 78605-78618 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.12522  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Apoptosis--drug effects<br/>Bortezomib--pharmacology<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Chemokine CCL27--metabolism<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Interleukin-10--genetics<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Proteasome Endopeptidase Complex--metabolism<br/>Proteasome Inhibitors--pharmacology<br/>RNA Interference<br/>Receptor Cross-Talk--drug effects<br/>Receptors, CCR10--genetics<br/>Receptors, Interleukin-10--genetics<br/>Signal Transduction--drug effects<br/>Transfection<br/>Tumor Microenvironment<br/>Xenograft Model Antitumor Assays